FTC request may signal trouble for Novo/Catalent deal

FTC request may signal trouble for Novo/Catalent deal

Source: 
Pharma Voice
snippet: 

The proposed deal between Novo Holdings and contract manufacturer Catalent may face headwinds from an increasingly aggressive U.S. Federal Trade Commission.